Association of the polymorphism Y402H in the CFH gene with response to anti‐VEGF treatment in age‐related macular degeneration: a systematic review and meta‐analysis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
To explore whether the complement factor H (CFH) polymorphism rs1061170/Y402H is associated with responsiveness to antivascular endothelial growth factor (VEGF) agents in age‐related macular degeneration (AMD). We reviewed the English literature to examine the association between the polymorphism rs1061170/Y402H of the CFH gene and responsiveness to treatment with anti‐VEGF drugs in AMD patients. A meta‐analysis of eligible studies was also performed. Pooled odds ratios (OR s) and 95% CI s were estimated using Stata V.12.0. Statistical heterogeneity was measured using Q‐statistic testing. Fourteen relevant studies including a total of 2963 AMD patients were eligible. In AMD patients without a treatment history, individuals carrying the rs1061170/Y402H TT genotype were more likely to achieve a better outcome (OR = 1.932, 95% CI = 1.125–3.317, p = 0.017) than those carrying the CC genotype. The polymorphism rs1061170/Y402H might be a genetic predictor of treatment response to anti‐VEGF therapy in AMD patients. Further prospective research including a larger number of patients is needed to validate this finding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Brantley, M. A., Fang, A. M., King, J. M., Tewari, A., Kymes, S. M., & Shiels, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.008 · Cited by 201
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142 · cited 1×
“…Smailhodzic et al. 2012; Tian et al. 2012; Yamashiro et al. 2012; Abedi et al. 2013; Chang et al. 2013; Dikmetas et al. 2013; Habibi et al. 2013; Hagstrom et al. 2013; Hautamaki et al. 2013, 2014; Kitchens et al. 2013; Lotery et al. 2013; Yuan et al. 2013; van Asten et al. 2014; Matsumiya et…”
BackgroundLee, A. Y., Raya, A. K., Kymes, S. M., Shiels, A., & Brantley, M. A. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150995 · Cited by 134
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD
Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6080 · Cited by 120 · cited 7×
“A total of 76 related published studies were identified by an initial screen, and 29 papers were chosen after further examination (Brantley et al. 2007; Lee et al. 2009; Imai et al. 2010; Teper et al. 2010; Kloeckener-Gruissem et al. 2011; Nischler et al. 2011; Kang et al. 2012; McKibbin et al. 2012; Menghini et al. 2…”
BackgroundInfluentialMcKibbin, M., Ali, M., Bansal, S., Baxter, P. D., West, K., Williams, G., Cassidy, F., & Inglehearn, C. F. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.193680 · Cited by 100
Lotery, A. J., Gibson, J., Cree, A. J., Downes, S. M., Harding, S. P., Rogers, C. A., Reeves, B. C., Ennis, S., & Chakravarthy, U. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.046 · Cited by 64
Orlin, A., Hadley, D., Chang, W., Ho, A. C., Brown, G., Kaiser, R. S., Regillo, C. D., Godshalk, A. N., Lier, A., Kaderli, B., et al. (2012) · Retina · doi:10.1097/iae.0b013e31822a2c7c · Cited by 60
Predicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration
van Asten, F., Rovers, M. M., Lechanteur, Y. T. E., Smailhodzic, D., Muether, P. S., Chen, J., den Hollander, A. I., Fauser, S., Hoyng, C. B., van der Wilt, G. J., et al. (2014) · Ophthalmic Epidemiology · doi:10.3109/09286586.2014.949010 · Cited by 37 · cited 1×
“…al. 2013; Dikmetas et al. 2013; Habibi et al. 2013; Hagstrom et al. 2013; Hautamaki et al. 2013, 2014; Kitchens et al. 2013; Lotery et al. 2013; Yuan et al. 2013; van Asten et al. 2014; Matsumiya et al. 2014; Park et al. 2014; Piermarocchi et al. 2014; Veloso et al. 2014; and Beykin et al. 2015).”
Background
Cited by
Genetics and genetic testing for age-related macular degeneration
Warwick, A., & Lotery, A. (2018) · Eye · doi:10.1038/eye.2017.245 · Cited by 67
Tzoumas, N., Hallam, D., Harris, C. L., Lako, M., Kavanagh, D., & Steel, D. H. W. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.10.008 · Cited by 33
Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential
Stradiotto, E., Allegrini, D., Fossati, G., Raimondi, R., Sorrentino, T., Tripepi, D., Barone, G., Inforzato, A., & Romano, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113280 · Cited by 29
Guymer, R. H., Silva, R., Ghadessi, M., Leal, S., Gashaw, I., Damask, A., Paulding, C., & Rittenhouse, K. D. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.8.17 · Cited by 6
“…have reported an association between anti-VEGF treatment response in nAMD and the A69S polymorphism (rs10490924) in the ARMS2 gene, 20 the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the CFH gene, 21,22 and the rs833061 polymorphism in the VEGFA gene.”
Metadata
- Authors
- Hong, N., Shen, Y., Yu, C., Wang, S., & Tong, J.
- Venue
- Acta Ophthalmologica
- Publisher
- Wiley
- Published
- 2016-05-06
- Volume
- 94
- Issue
- 4
- Pages
- 334-345
- ISSN
- 0001-639X (ISSN-L)
- 1755-375X
- 1755-3768
- OpenAlex
- W2346153654
- Cited by
- 37
- References
- 10
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of the polymorphism Y402H in the CFH gene with response to anti‐VEGF treatment in age‐related macular degeneration: a systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/aos.13049
- The paper
- Hong, N., Shen, Y., Yu, C., Wang, S., & Tong, J. (2016). Association of the polymorphism Y402H in the CFH gene with response to anti‐VEGF treatment in age‐related macular degeneration: a systematic review and meta‐analysis. Acta Ophthalmologica. https://doi.org/10.1111/aos.13049
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.